Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Analytical Biochemistry|January 31, 2004
A continuous nonradioactive assay for RNA-dependent RNA polymerase activityFrederick C Lahser, Bruce A Malcolm
Journal of Virology|December 25, 2003
Conserved C-terminal threonine of hepatitis C virus NS3 regulates autoproteolysis and prevents product inhibitionWenyan Wang, Frederick C Lahser, MinKyung Yi, et al.
Virus Research|September 9, 2005
Trans-complementation of HCV replication by non-structural protein 5AXiao Tong, Bruce A Malcolm
Antimicrobial Agents and Chemotherapy|April 19, 2017
Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 RepliconsErnest Asante-Appiah, Stephanie Curry, Patricia McMonagle, et al.
Virology|August 13, 2010
A comparative analysis of the substrate permissiveness of HCV and GBV-B NS3/4A proteases reveals genetic evidence for an interaction with NS4B protein during genome replicationYann Benureau, Lucile Warter, Bruce A Malcolm, et al.
Antimicrobial Agents and Chemotherapy|March 2, 2016
The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a RepliconsFrederick C Lahser, Karin Bystol, Stephanie Curry, et al.
Virology|June 5, 2003
The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNASifang Zhou, Rong Liu, Bahige M Baroudy, et al.
Antiviral Research|February 2, 2006
Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034Xiao Tong, Robert Chase, Angela Skelton, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|April 23, 2015
Half-life extension of the HIV-fusion inhibitor peptide TRI-1144 using a novel linker technologyEric L Schneider, Gary W Ashley, Lieve Dillen, et al.
Antimicrobial Agents and Chemotherapy|May 1, 2013
Identification of PTC725, an orally bioavailable small molecule that selectively targets the hepatitis C Virus NS4B proteinZhengxian Gu, Jason D Graci, Frederick C Lahser, et al.
Pageof 2